Results 61 to 70 of about 31,486 (223)
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study
Arthritis &Rheumatology, EarlyView.Objective
The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods
This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian +35 morewiley +1 more sourceEfficacy of colchicine in addition to anakinra in patients with recurrent pericarditis
Open HeartAim Anakinra, an anti IL-1 agent targeting IL-1 alfa and beta, is available for the treatment of recurrent pericarditis in cases with corticosteroid dependence and colchicine resistance after failure of conventional therapies.Allan L Klein, Antonio Abbate, Massimo Imazio, George Lazaros, Antonio Brucato, Luca Cantarini, Marco Merlo, Gianfranco Sinagra, Alessandro Andreis, Valentino Collini, Maria De Martino, Marzia De Biasio, Miriam Isola, Nicole Croatto, Veronica Lepre +14 moredoaj +1 more sourceAnakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
PLoS ONE, 2023 BackgroundAnakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of Jonas Sundén-Cullberg, Puran Chen, Henrike Häbel, Paul Skorup, Helena Janols, Johan Rasmuson, Katarina Niward, Åse Östholm Balkhed, Katerina Chatzidionysiou, Hilmir Asgeirsson, Ola Blennow, Åsa Parke, Anna-Karin Svensson, Jagadeeswara Rao Muvva, Hans-Gustav Ljunggren, Karolinska KI/K COVID-19 Treatment Working Group, Anna-Carin Horne, Ulrika Ådén, Jan-Inge Henter, Anders Sönnerborg, Jan Vesterbacka, Piotr Nowak, Jon Lampa +22 moredoaj +1 more sourceDevelopment of a peptide-siRNA nanocomplex targeting NF- κB for efficient cartilage delivery [PDF]
, 2019 Delivery of therapeutic small interfering RNAs (siRNAs) in an effective dose to articular cartilage is very challenging as the cartilage dense extracellular matrix renders the chondrocytes inaccessible, even to intra-articular injections. Herein, we used Akk, Antonina, Duan, Xin, Pan, Hua, Pham, Christine T. N., Rai, Muhammad Farooq, Sandell, Linda J., Wickline, Samuel A., Yan, Huimin +7 morecore +3 more sourcesEffect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN‐DU Cohort
Arthritis &Rheumatology, EarlyView.Objective
To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of patients with juvenile idiopathic arthritis (JIA). Methods
The international UCAN CAN‐DU study prospectively enrolled patients with JIA across Canada and the Netherlands.Jelleke B. de Jonge, Sytze de Roock, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Deborah A. Marshall, Sebastiaan J. Vastert, Rae S. M. Yeung, Joost F. Swart, Susanne M. Benseler, on behalf of the UCAN CAN‐DU and UCAN CURE consortia, Adam Huber, Bianca Lang, Chelsea DeCoste, Elizabeth Stringer, Suzanne Ramsey, Alan Rosenberg, Kate Neufeld, Mehul Jariwala, Tristan Kerr, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Arthur Cheng, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Deborah Levy, Dilan Dissanayake, Elizaveta Limenis, Evelyn Rozenblyum, Harper Cheng, Jennifer Ji Young Lee, Lynn Spiegel, Rayfel Schneider, Ronald Laxer, Ruud Verstegen, Shirley Tse, Trang Duong, Andrea Human, David Cabral, Herman Tam, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Mercedes Chan, Ross Petty, Tommy Gerschman, Annet van Royen‐Kerkhof, Berent Prakken, Erika Van Nieuwenhove, Marc Jansen, Nico Wulffraat, Ciarán Duffy, Nadia Luca, Roman Jurencak, Tala El Tal, Claire LeBlanc, Gaëlle Chédeville, Piya Lahiry, Rosie Scuccimarri, Sarah Campillo, Clare Hutchinson, Daniah Basodan, Dax G. Rumsey, Hon Yan Ng, Jeanine McColl, Lillian Lim, Tara McGrath, Danielle Brinkman, Petra Hissink Muller, Elizabeth Legger, Wineke Armbrust, Ellen Schatorje, Esther Hoppenreijs, Elodie Boudes, Gillian Currie, Heinrike Schmeling, Muhammed Dhalla, Nicole Johnson, Paivi Miettunen, Ravneet Sran, Rebeka Stevenson, Erkan Demirkaya, Jonathan Park, Roberta Berard, Giske Biesbroek, Mariken Gruppen, Gordon Soon, Joseph Cafazzo, Liane Heale, Michelle Batthish, Tania Cellucci, Lily Lim, Maarten IJzerman, Marinka Twilt, Marleen Verkaaik, Philomine van Pelt, Sylvia Kamphuis, Michelle Kip, Nickolas Blanchette, Paul Dancey, Regina de Geus +102 morewiley +1 more sourceAnakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
Frontiers in Immunology, 2022 BackgroundBronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely.Elys A. Green, Elys A. Green, Elys A. Green, David Metz, David Metz, David Metz, Robert Galinsky, Rebecka Atkinson, Rebecka Atkinson, Elizbeth M. Skuza, Megan Clark, Megan Clark, Alistair J Gunn, Carl M. Kirkpatrick, Rod W. Hunt, Rod W. Hunt, Rod W. Hunt, Philip J. Berger, Claudia A. Nold-Petry, Claudia A. Nold-Petry, Marcel F. Nold, Marcel F. Nold, Marcel F. Nold +22 moredoaj +1 more sourceTreatment of adult-onset Still's disease: a review [PDF]
, 2014 Adult-onset Still's disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. The former classification, based on the disease course, seems to be quite dated.Gerfaud-Valentin, M., Henry, T., Jamilloux, Y., Seve, P. +3 morecore +3 more sourcesInterleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors
Arthritis &Rheumatology, Accepted Article.Objective
To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna de Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe +8 morewiley +1 more sourceChronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells [PDF]
, 2017 Skeletal complications are common features of neonatal-onset multisystem inflammatory disease (NOMID), a disorder caused by NLRP3-activating mutations. NOMID mice in which NLRP3 is activated globally exhibit several characteristics of the human disease ...Abu-Amer, Yousef, Alippe, Yael, Civitelli, Roberto, Mbalaviele, Gabriel, Qu, Chao, Schipani, Ernestina, Wang, Chun, Xiao, Jianqiu, Xu, Can-Xin +8 morecore +2 more sourcesSystemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract
Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li +7 morewiley +1 more source
